For decades, the price of insulin has stood as one of the starkest symbols of a healthcare system that places profit above survival. Beginning January 1, California will attempt something no state has tried before — producing and selling its own insulin under the CalRx brand at $55 per five-pack, using the weight of its economy to circumvent the pharmaceutical pricing machinery that has forced millions to ration a drug they cannot live without. It is, at its core, a wager that collective power, wielded by a government on behalf of its people, can accomplish what the market has refused to.
California Launches Low-Cost Insulin Program, Challenging Pharma Pricing
Diabetes patients who ration insulin due to cost will gain access to affordable medication, potentially preventing serious health complications and financial hardship.
California didn't wait—we took matters into our own hands
Mark
Why did California feel it had to manufacture insulin itself rather than just negotiate harder with existing companies?
Mimi
Because negotiation assumes the other side has incentive to move. These manufacturers have been raising prices for decades with almost no consequence. California decided the only real leverage was to become a competitor, not a customer.
Mark
But can a state actually run a drug manufacturing operation? Isn't that incredibly complex?
Mimi
It's complex, but California isn't building the factory from scratch. They partnered with Civica Rx, a nonprofit that already does this work, and Biocon Biologics, which has the technical expertise. The state is using its buying power and regulatory authority, not reinventing the wheel.
Mark
What happens to the people who've been rationing insulin while waiting for this?
Mimi
That's the human reality underneath the policy. They start January 1. But there are people who've already suffered complications, gone into debt, or died because they couldn't afford the drug. This program doesn't undo that damage.
Mark
Will other states copy this model?
Mimi
Almost certainly, if it works. Every state has diabetic residents paying unsustainable prices. The question is whether they have the political will and the economic scale to pull it off. California's size gives it advantages smaller states don't have.
Mark
What's the pharmaceutical industry saying about all this?
Mimi
They're quiet so far, which is telling. They can't argue the state shouldn't be allowed to do this—it's legal. What they'll likely do is compete on price in California while maintaining higher prices elsewhere, or they'll lobby Congress to restrict state drug programs. The real fight is probably still coming.
Il Polso
- Millions of American diabetics have long faced an impossible arithmetic — insulin prices rising from $25 to $300 over a generation, forcing life-or-death rationing decisions at kitchen tables across the country.
- California's CalRx program launches January 1, offering biosimilar insulin pens at $55 retail — a price that undercuts name-brand alternatives costing up to $411 for the same quantity.
- The state bypasses insurers, pharmacy benefit managers, and Big Pharma entirely by partnering with nonprofit manufacturer Civica Rx and Biocon Biologics, becoming both producer and seller.
- Federal efforts — from Trump-era to Biden-era Medicare caps at $35 — addressed only a fraction of the uninsured and underinsured population still left exposed to predatory pricing.
- If CalRx holds its price point and sustains quality, the model could ripple outward, pressuring other states and the federal government to rethink who controls the supply of essential medicines.
For decades, the price of insulin has stood as one of the starkest symbols of a healthcare system that places profit above survival. Beginning January 1, California will attempt something no state has tried before — producing and selling its own insulin under the CalRx brand at $55 per five-pack, using the weight of its economy to circumvent the pharmaceutical pricing machinery that has forced millions to ration a drug they cannot live without. It is, at its core, a wager that collective power, wielded by a government on behalf of its people, can accomplish what the market has refused to.
California is about to do something no other state has attempted: sell its own insulin. Starting January 1, residents can purchase CalRx-branded insulin pens for no more than $55 per five-pack — a direct challenge to pharmaceutical pricing that has made a life-sustaining drug unaffordable for millions.
The program was built through a partnership with nonprofit generic manufacturer Civica Rx and Biocon Biologics. The insulin is an interchangeable biosimilar of glargine, a widely used long-acting insulin. Pharmacies will acquire the pens for $45 — compared to the $89 to $411 that name-brand manufacturers charge for the same quantity. That gap is the entire argument.
Governor Gavin Newsom framed the initiative as an act of necessity rather than patience. California, he argued, could not wait for the industry to reform itself. With the state's population and purchasing power, it can negotiate directly with manufacturers in ways no individual patient ever could — and then pass those savings on without the layers of middlemen who have historically captured the difference.
The insulin pricing crisis has deep roots. A 2017 class-action lawsuit accused Eli Lilly, Sanofi, and Novo Nordisk of systematically inflating prices year after year. The drug became a political symbol, cited across party lines. Both Trump and Biden claimed credit for capping Medicare insulin costs at $35 — a meaningful but partial fix that left the uninsured and underinsured still exposed. In 2024, the federal government sued pharmacy benefit managers for their role in sustaining the price spiral.
CalRx sidesteps that entire apparatus. By producing its own supply, the state eliminates the markup chain and offers Californians a genuine alternative. Whether the program can sustain its price point and quality will determine whether other states follow — or whether the pharmaceutical industry's skepticism about government-run drug production finds its proof.
California is about to do something no other state has attempted: manufacture and sell its own insulin. Starting January 1, residents will be able to buy CalRx-branded insulin pens for no more than $55 per five-pack—a move that directly challenges the pharmaceutical industry's stranglehold on a drug that millions of Americans depend on to survive.
The program emerged from a partnership between California, the nonprofit generic manufacturer Civica Rx, and Biocon Biologics. The insulin being produced is an interchangeable biosimilar version of glargine, a long-acting insulin used to manage blood sugar in people with diabetes. Pharmacies will acquire the pens for $45 per five-pack, a dramatic discount compared to what name-brand manufacturers charge: between $89 and $411 for the same quantity. That gap—the difference between what the state can produce and what the market has been paying—is the entire story.
Governor Gavin Newsom framed the move as an act of necessity. "California didn't wait for the pharmaceutical industry to do the right thing," he said in announcing the program. "We took matters into our own hands." The CalRx initiative, which Newsom has positioned as a cornerstone of his administration, represents a rare instance of a state using its economic leverage to bypass corporate pricing altogether. With California's population and purchasing power, the state can negotiate directly with manufacturers in ways individual patients never could.
The insulin pricing crisis did not emerge overnight. In 2017, a class-action lawsuit accused the three largest insulin manufacturers—Eli Lilly, Sanofi, and Novo Nordisk—of systematically raising prices year after year. Court documents alleged that prescriptions costing patients $25 in earlier years had climbed to $300. The drug became a symbol of pharmaceutical price gouging, cited by politicians across the spectrum. Both President Donald Trump and former President Joe Biden claimed credit for capping insulin costs for Medicare recipients at $35, a federal intervention that addressed only a portion of the population.
Yet even as prices have moderated somewhat in recent years, the underlying problem persisted. In 2024, the federal government sued pharmacy benefit managers, accusing them of fueling the price spiral. The system remained fundamentally broken for most Americans: those without Medicare coverage, those with high deductibles, and those without insurance at all continued to face choices between buying insulin and paying rent.
What California is doing sidesteps that entire apparatus. By producing its own supply through established manufacturers, the state becomes both buyer and seller, eliminating the middlemen and the markup. The CalRx insulin pens are interchangeable with Lantus, a widely prescribed long-acting insulin, meaning patients and doctors can treat them as equivalent options. The state is betting that offering a genuinely affordable alternative will force the market to respond—or at least give Californians a way out.
The program's success or failure will likely determine whether other states follow. If California can sustain production, maintain quality, and actually deliver on the promised price point, the model becomes replicable. If it stumbles, the pharmaceutical industry's argument that price controls are impossible gains credibility. Either way, the experiment has already shifted the conversation. A state has called the industry's bluff and said: we can do this ourselves.
Citazioni salienti
No Californian should ever have to ration insulin or go into debt to stay alive— Governor Gavin Newsom
Vuoi la storia completa?
Leggi l'originale su Newsmax ↗
Health & Medicine